Azenta (AZTA) FY2025 results: revenue $594 million, up 3.6% on the year
Azenta, Inc. (AZTA) reported revenue of $594 million for fiscal 2025, the year ended 30 September 2025, up 3.6% on the year before. Net income was -$56 million, and diluted earnings per share $-1.22. The figures are the company's own, from the 10-K it filed with the SEC on 4 December 2025.
Revenue
$594 million
+3.6% on the year
FY2018FY2025
Operating margin
-4.5%
-8.9% a year earlier
FY2018FY2025
Net income
-$56 million
FY2018FY2025
Diluted EPS
-$1.22
FY2018FY2025
this yearthe year beforeHover a bar for its figure.
The year in brief
What management said about the year
Guidance figures: 2 new.
Fourth-quarter revenue rose 6%: Revenue was $159 million, up 6%. Organic growth was 4%, mainly from higher Multiomics revenue.
Adjusted EBITDA rose 29%: Quarterly adjusted EBITDA was $21 million, a 13.0% margin. Full-year adjusted EBITDA was $66 million, an 11.2% margin.
Multiomics led quarterly growth: Multiomics quarterly revenue rose 11% from $66 million a year earlier, with organic growth of 10%.
Cash and securities of $546 million: Cash, restricted cash and marketable securities totalled $546 million at fiscal year-end, September 30, 2025.
Organic growth target of 3% to 5%: Management expects fiscal 2026 organic revenue growth of 3% to 5% after fiscal 2025 organic growth of 3%.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2025
FY2024
FY2023
On the year
Last 8 years
Operating cash flow
72.2
49.7
5.8
+45.1%
Capital expenditure
33.9
37.4
39.4
-9.5%
Free cash flow
38.3
12.4
-33.6
+210.3%
Free cash flow margin
6.5%
2.2%
-6.1%
Cash from investing
-90.5
225
431
Cash from financing
-9.6
-659
-840
Depreciation and amortisation
61.2
90.7
85.6
-32.5%
Share-based compensation
20.9
14.5
9.4
+44.3%
Buybacks
0.0
662
839
Dividends paid
n/a
0.0
0.0
Diluted shares, weighted
46m
53m
66m
-13.7%
Shares outstanding at period end
46m
46m
58m
+0.6%
Balance sheet
$ million
FY2025
FY2024
FY2023
On the year
Last 8 years
Shareholders' equity
1,727
1,769
2,534
-2.4%
Debt
0.0
0.0
0.0
Operating lease liabilities
51.2
56.7
60.4
-9.6%
Finance lease liabilities
0.9
1.0
1.4
-7.4%
Other liabilities
280
273
289
+2.6%
Total liabilities and equity
2,060
2,100
2,886
-1.9%
Goodwill
702
691
675
+1.6%
Intangible assets
102
125
294
-18.6%
Investments
263
201
450
+31.0%
Cash and equivalents
280
280
649
-0.1%
Receivables
142
154
157
-7.8%
Inventory
75.0
71.3
128
+5.1%
Other assets
496
577
532
-14.2%
Total assets
2,060
2,100
2,886
-1.9%
10-K for the year ended 30 September 2025, filed 4 December 2025: the filing.